The emergence of vacuum‑assisted breast biopsy (VABB) technology is far more than a technical improvement in the field of breast biopsy. Essentially, it has profoundly reshaped the entire clinical diagnosis and management pathway of breast diseases, especially breast cancer. As a manufacturer of this critical device, our vision has long transcended merely "producing a functional needle". We focus more on how this needle integrates into and optimises the complete chain from imaging detection and pathological diagnosis to treatment decision‑making, acting as a core pivot driving the implementation of precision medicine. From a clinical perspective, this article analyses how VABB needles change the rules of the game.

From Suspicion to Definitive Diagnosis: A Paradigm Shift in Diagnostic Efficiency

Before the widespread application of VABB, lesions classified as BI‑RADS 4 (suspicious for malignancy) on breast imaging - particularly deep, tiny lesions presenting only as clustered microcalcifications - often posed diagnostic challenges. Conventional fine‑needle aspiration cytology yields small, unrepresentative samples with limited diagnostic accuracy. While open surgical biopsy delivers reliable results, it causes severe trauma, incurs high costs, and leaves scars, imposing significant physical and psychological burdens on patients.

Featuring large gauge sizes (e.g. 10G, 12G) and a vacuum‑assisted aspiration mechanism, VABB needles can obtain sufficient, continuous tissue strips in a single procedure, with sample volumes dozens of times larger than those from conventional core needle biopsy. This enables pathologists not only to make clearer benign‑malignant diagnoses but also to conduct comprehensive histological typing, grading, and key immunohistochemical testing. It converts numerous cases requiring diagnostic surgery into minimally invasive outpatient procedures, achieving dual breakthroughs in efficiency and accuracy from tentative suspicion to definitive diagnosis. It avoids unnecessary surgical trauma and greatly alleviates patient anxiety.

Paving the Way for Precision Treatment: A Qualified Sample Provider in the Era of Biomarkers

Modern breast cancer treatment has entered a precision‑based era of stratified therapy. Treatment selection relies heavily on the status of biomarkers such as oestrogen receptor, progesterone receptor, HER2 and Ki‑67. Small samples from traditional biopsy methods are often insufficient for complete testing, potentially leading to incomplete information for treatment decisions.

High‑quality, intact core tissue specimens obtained via VABB provide ideal material for comprehensive biomarker detection. This ensures a complete molecular profile is available prior to treatment initiation, laying a solid foundation for formulating chemotherapy, endocrine therapy or targeted therapy regimens. One core objective for manufacturers continuously optimising needle notch design and cutting efficiency is to ensure extracted tissue strips feature abundant volume, well‑preserved cellular structures and intact antigens, meeting the stringent requirements of modern molecular pathology. In this sense, VABB needles serve as an irreplaceable bridge linking imaging abnormalities to precision treatment plans.

Expanding New Frontiers: Cross‑Boundary Evolution from Diagnosis to Minimally Invasive Therapy

The value of VABB extends beyond diagnosis. For small benign masses such as fibroadenomas, VABB enables complete percutaneous minimally invasive resection through multiple‑site sampling during biopsy. Patients require no open surgery and recover with only pinhole‑sized wounds, delivering excellent cosmetic outcomes. This expands the application scope of the technology, evolving it from a purely diagnostic tool into an integrated diagnostic‑therapeutic device.

Furthermore, VABB can obtain baseline tissue samples before neoadjuvant therapy for breast cancer to assess pre‑treatment biomarker status. Post‑treatment repeat biopsy via VABB can evaluate the pathological complete response rate, providing evidence for subsequent treatment decisions. VABB needles thus become a reliable tool for dynamically monitoring treatment response.

Optimising Clinical Workflows and Patient Experience: Promoting Day‑Case Surgery and Multidisciplinary Collaboration

VABB procedures are generally performed under local anaesthesia with short operation times and rapid post‑operative recovery, enabling true day‑case surgery. This significantly conserves medical resources, improves bed turnover and benefits patients. Meanwhile, the adoption of VABB greatly strengthens multidisciplinary collaboration among radiology, breast surgery and pathology departments. Real‑time image guidance ensures precise and traceable sampling locations, with pathological reports directly correlated to imaging findings. Such close collaboration elevates overall diagnosis and treatment standards, making VABB standard equipment in modern breast disease diagnosis and treatment centres.

As manufacturers of vacuum‑assisted breast biopsy needles, we fully recognise that our products form a vital link within a complex clinical value chain. We not only enhance the success rate of single biopsies and sample quality through precision manufacturing but also understand how technology transforms clinical pathways and patient journeys through continuous engagement with clinical experts. We act as enablers and supporters of clinical change. What we provide is not merely a set of devices, but a solution driving breast disease diagnosis and treatment toward greater precision, minimal invasiveness and higher efficiency. Against the backdrop of the Healthy China Initiative and national strategies for early diagnosis and treatment of cancer, continuous optimisation of VABB technology represents the fundamental yet core manufacturing force for improving overall breast cancer diagnosis and treatment standards.